Design, synthesis, and biological evaluation of deuterated C-aryl glycoside as a potent and long-acting renal sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes

Journal of Medicinal Chemistry

Volumn 57, Issue 4, 2014, Pages 1236-1251

  Xu, Ge ^a,b   Lv, Binhua ^b   Roberge, Jacques Y ^b   Xu, Baihua ^b   Du, Jiyan ^b   Dong, Jiajia ^b   Chen, Yuanwei ^b   Peng, Kun ^b   Zhang, Lili ^b   Tang, Xinxing ^b   Feng, Yan ^b   Xu, Min ^b   Fu, Wei ^a   Zhang, Wenbin ^b   Zhu, Liangcheng ^b   Deng, Zhongping ^b   Sheng, Zelin ^b   Welihinda, Ajith ^c   Sun, Xun ^a  

^a FUDAN UNIVERSITY   (China)

^b Egret Pharma (Shanghai) Limited   (China)

^c Theracos Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ARYL GLYCOSIDE; GLYCOSIDE; LONG ACTING DRUG; METHYL D3 4 METHYLBENZENESULFONATE; SODIUM GLUCOSE COTRANSPORTER 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG METABOLISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; EXPERIMENTAL DOG; GLUCOSE URINE LEVEL; GLUCOSURIA; IC 50; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLYCOSIDES; MAGNETIC RESONANCE SPECTROSCOPY; RATS; RATS, SPRAGUE-DAWLEY; SODIUM-GLUCOSE TRANSPORTER 2; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84896850159     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401780b     Document Type: Article

References (53)

1. World Health Organization diabetes fact sheet (no. 312). http://www.who.int/mediacentre/factsheets/fs312 (accessed August 2013).
2. Facchini, F. S.; Hua, N.; Abbasi, F.; Reaven, G. M. Insulin resistance as a predictor of age-related diseases J. Clin. Endocrinol. Metab. 2001, 86, 3574-3578
3. Stumvoll, M.; Goldstein, B. J.; van Haeften, T. W. Type 2 diabetes: Principles of pathogenesis and therapy Lancet 2005, 365, 1333-1346
4. Davidson, M. B.; Peters, A. L. An overview of metformin in the treatment of type 2 diabetes mellitus Am. J. Med. 1997, 102, 99-110
5. Horii, S.; Fukase, H.; Matsuo, T.; Kameda, Y.; Asano, N.; Matsui, K. Synthesis and R- d -glucosidase inhibitory activity of N-substituted valiolamine derivatives as potential oral antidiabetic agents J. Med. Chem. 1986, 29, 1038-1046
6. Davis, S. N. The role of glimepiride in the effective management of type 2 diabetes J. Diabetes Complications 2004, 18, 367-376
7. Marco, S.; Michael, P.; Adrian, R.; Hubert, H.; Sander, K.; Hugo, A.; Torsten, S.; Urs, A. M.; Christoph, R. Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor γ activity: A combined virtual screening and biological assay approach Mol. Pharmacol. 2007, 71, 398-406
8. Ajjan, R. A.; Grant, P. J. The cardiovascular safety of rosiglitazone Expert Opin. Drug Saf. 2008, 7, 367-376
9. Momose, Y.; Meguro, K.; Ikeda, H.; Hatanaka, C.; Oi, S.; Shoda, T. Studies on antidiabetic agents. X. Synthesis and biological activities of pioglitazone and related compounds Chem. Pharm. Bull. 1991, 39, 1440-1445
10. Kim, D.; Wang, L.; Beconi, M.; Eiermann, G. J.; Fisher, M. H.; He, H.; Hickey, G. J.; Kowalchick, J. E.; Leiting, B.; Lyons, K.; Marsilio, F.; McCann, M. E.; Patel, R. A.; Petrov, A.; Scapin, G.; Patel, S. B.; Roy, R. S.; Wu, J. K.; Wyvratt, M. J.; Zhang, B. B.; Zhu, L.; Thornberry, N. A.; Weber, A. E. (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-R]pyrazin-7(8H) -yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J. Med. Chem. 2005, 48, 141-151
11. Dicker, D. DPP-4 inhibitors. Impact on glycemic control and cardiovascular risk factors Diabetes Care 2011, 34, S276-S278
12. Vallon, V.; Platt, K. A.; Cunard, R.; Schroth, J.; Whaley, J.; Thomson, S. C.; Koepsell, H.; Rieg, T. SGLT2 mediates glucose reabsorption in the early proximal tubule J. Am. Soc. Nephrol. 2011, 22, 104-112
13. +/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for d -glucose J. Clin. Invest. 1994, 93, 397-404
14. Powell, D. R.; DaCosta, C. M.; Gay, J.; Ding, Z. M.; Smith, M.; Greer, J.; Doree, D.; Jeter-Jones, S.; Mseeh, F.; Rodriguez, L. A.; Harris, A.; Buhring, L.; Platt, K. A.; Vogel, P.; Brommage, R.; Shadoan, M. K.; Sands, A. T.; Zambrowicz, B. Improved glycemic control in mice lacking Sglt1 and Sglt2 Am. J. Physiol.: Endocrinol. Metab. 2013, 304, E117-E130
15. Chao, E. C.; Henry, R. R. SGLT2 inhibition-a novel strategy for diabetes treatment Nat. Rev. Drug Discovery 2010, 9, 551-559
16. +, d -glucose cotransporter. A model Biochim. Biophys. Acta 1982, 688, 557-571
17. Ehrenkranz, J. R.; Lewis, N. G.; Kahn, C. R.; Roth, J. Phlorizin: A review Diabetes/Metab. Res. Rev. 2005, 21, 31-38
18. +-glucose cotransporters, may provide a novel approach to treating diabetes Diabetes 1999, 48, 1794-1800
19. +-glucose cotransporter (SGLT) inhibitors as antidiabetic agents. 4. Synthesis and pharmacological properties of 4′-dehydroxyphlorizin derivatives substituted on the B ring J. Med. Chem. 1999, 42, 5311-5324
20. Katsuno, K.; Fujimori, Y.; Takemura, Y.; Hiratochi, M.; Itoh, F.; Komatsu, Y.; Fujikura, H.; Isaji, M. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level J. Pharmacol. Exp. Ther. 2007, 320, 323-330
21. Fujimori, Y.; Katsuno, K.; Nakashima, I.; Ishikawa-Takemura, Y.; Fujikura, H.; Isaji, M. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models J. Pharmacol. Exp. Ther. 2008, 327, 268-276
22. Meng, W.; Ellsworth, B. A.; Nirschl, A. A.; McCann, P. J.; Patel, M.; Girotra, R. N.; Wu, G.; Sher, P. M.; Morrison, E. P.; Biller, S. A.; Zahler, R.; Deshpande, P. P.; Pullockaran, A.; Hagan, D. L.; Morgan, N.; Taylor, J. R.; Obermeier, M. T.; Humphreys, W. G.; Khanna, A.; Discenza, L.; Robertson, J. G.; Wang, A.; Han, S.; Wetterau, J. R.; Janovitz, E. B.; Flint, O. P.; Whaley, J. M.; Washburn, W. N. Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes J. Med. Chem. 2008, 51, 1145-1149
23. Nomura, S.; Sakamaki, S.; Hongu, M.; Kawanishi, E.; Koga, Y.; Sakamoto, T.; Yamamoto, Y.; Ueta, K.; Kimata, H.; Nakayama, K.; Tsuda-Tsukimoto, M. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus J. Med. Chem. 2010, 53, 6355-6360
24. Imamura, M.; Nakanishi, K.; Suzuki, T.; Ikegai, K.; Shiraki, R.; Ogiyama, T.; Murakami, T.; Kurosaki, E.; Noda, A.; Kobayashi, Y.; Yokota, M.; Koide, T.; Kosakai, K.; Ohkura, Y.; Takeuchi, M.; Tomiyama, H.; Ohta, M. Discovery of ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus Bioorg. Med. Chem. 2012, 20, 3263-3279
25. Goodwin, N. C.; Mabon, R.; Harrison, B. A.; Shadoan, M. K.; Almstead, Z. Y.; Xie, Y.; Healy, J.; Buhring, L. M.; DaCosta, C. M.; Bardenhagen, J.; Mseeh, F.; Liu, Q.; Nouraldeen, A.; Wilson, A. G. E.; Kimball, S. D.; Powell, D. R.; Rawlins, D. B. Novel l -xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes J. Med. Chem. 2009, 52, 6201-6204
26. Mascitti, V.; Maurer, T. S.; Robinson, R. P.; Bian, J.; Boustany-Kari, C. M.; Brandt, T.; Collman, B. M.; Kalgutkar, A. S.; Klenotic, M. K.; Leininger, M. T.; Lowe, A.; Maguire, R. J.; Masterson, V. M.; Miao, Z.; Mukaiyama, E.; Patel, J. D.; Pettersen, J. C.; Préville, C.; Samas, B.; She, L.; Sobol, Z.; Steppan, C. M.; Stevens, B. D.; Thuma, B. A.; Tugnait, M.; Zeng, D.; Zhu, T. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors J. Med. Chem. 2011, 54, 2952-2960
27. Zhang, W.; Welihinda, A.; Mechanic, J.; Ding, H.; Zhu, L.; Lu, Y.; Deng, Z.; Sheng, Z.; Lv, B.; Chen, Y.; Roberge, J. Y.; Seed, B.; Wang, Y. EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA1c levels in db/db mice and prolongs the survival of stroke-prone rats Pharmacol. Res. 2011, 63, 284-293
28. Cai, M.; Liu, Q.; Xu, G.; Lv, B.; Seed, B.; Roberge, J. Y. Crystalline form of benzylbenzene SGLT2 inhibitor. PCT Int. Appl. WO2011153953, 2011.
29. Mayer, P. Chances and risks of SGLT2 inhibitors Naunyn-Schmiedeberg's Arch. Pharmacol. 2011, 1-4
30. Dahl, S. G. Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects Ther. Drug Monit. 1982, 4, 33-40
31. Rogan, E. G.; Badawi, A. F.; Devanesan, P. D.; Meza, J. L.; Edney, J. A.; West, W. W.; Higginbotham, S. M.; Cavalieri, E. L. Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: Potential biomarkers of susceptibility to cancer Carcinogenesis 2003, 24, 697-702
32. Wu, Y.; Davis, C. D.; Dworetzky, S.; Fitzpatrick, W. C.; Harden, D.; He, H.; Knox, R. J.; Newton, A. E.; Philip, T.; Polson, C.; Sivarao, D. V.; Sun, L.; Tertyshnikova, S.; Weaver, D.; Yeola, S.; Zoeckler, M.; Sinz, M. W. Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: Identification of (S)-N-[1-(4-fluoro-3-morpholin-4-ylphenyl)ethyl]-3-(4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition J. Med. Chem. 2003, 46, 3778-3781
33. Benz, C. C.; Atsriku, C.; Yau, C.; Britton, D.; Schilling, B.; Gibson, B. W.; Baldwin, M. A.; Scott, G. K. Novel pathways associated with quinone-induced stress in breast cancer cells Drug Metab. Rev. 2006, 38, 601-613
34. Yao, M.; Cao, K.; Zhang, D.; Rodrigues, D.; Humphreys, W. G.; Zhu, M. Identification of the human UDP-glucuronosyltransferase enzymes involved in glucuronidation of dapagliflozin. American Association of Pharmaceutical Scientists Annual Meeting, Los Angeles, CA, November 8-12, 2009; T3130.
35. Obermeier, M.; Yao, M.; Khanna, A.; Koplowitz, B.; Zhu, M.; Li, W.; Komoroski, B.; Kasichayanula, S.; Discenza, L.; Washburn, W.; Meng, W.; Ellsworth, B. A.; Whaley, J. M.; Humphreys, W. G. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II (SGLT2) inhibitor, in animals and humans Drug Metab. Dispos. 2010, 38, 405-414
36. Meanwell, N. A. Synopsis of some recent tactical application of bioisosteres in drug design J. Med. Chem. 2011, 54, 2529-2591
37. Maltais, F.; Jung, Y. C.; Chen, M.; Tanoury, J.; Perni, R. B.; Mani, N.; Laitinen, L.; Huang, H.; Liao, S.; Gao, H.; Tsao, H.; Block, E.; Ma, C.; Shawgo, R. S.; Town, C.; Brummel, C. L.; Howe, D.; Pazhanisamy, S.; Raybuck, S.; Namchuk, M.; Bennani, Y. L. In vitro and in vivo isotope effects with hepatitis C protease inhibitors: Enhanced plasma exposure of deuterated telaprevir versus telaprevir in rats J. Med. Chem. 2011, 52, 4993-8001
38. Sanderson, K. Big interest in heavy drugs Nature 2009, 458, 269
39. Yarnell, A. T. Heavy-hydrogen drugs turn heads, again. Firms seek to improve drug candidates by selective deuterium substitution Chem. Eng. News 2009, 87, 36-39
40. Schneider, F.; Hillgenberg, M.; Koytchev, R.; Alken, R.-G. Enhanced plasma concentration by selective deuteration of rofecoxib in rats Arzneim. Forsch. 2006, 56, 295-300
41. Buteau, K. C. Deuterated drugs: Unexpectedly nonobvious? J. High Tech. Law 2009, 22-74
42. Seed, B.; Lv, B.; Roberge, J. Y.; Chen, Y.; Peng, K.; Dong, J.; Xu, B.; Du, J.; Zhang, L.; Tang, X.; Xu, G.; Feng, Y.; Xu, M. Deuterated benzylbenzene derivatives and methods of use. PCT Int. Appl. WO2010009243, 2011.
43. Smonou, I. One step reduction of diaryl ketones to hydrocarbons by etherated boron trifluoride-triethylsilane system Synth. Commun. 1994, 24, 1999-2002
44. Nordlander, J. E.; Payne, M. J.; Njoroge, F.; Balk, M. A.; Laikos, G. D.; Vishwanath, V. M. Friedel-Crafts acylation with N-(trifluoroacetyl)-Cu-amino acid chlorides. Application to the preparation of β-arylalkylamines and 3-substituted 1,2,3,4-tetrahydroisoquinolines J. Org. Chem. 1984, 49, 4107-4111
45. Davis, F. A.; Clark, C.; Kumar, A.; Chen, B.-C. Asymmetric synthesis of the AB ring segments of daunomycin and 4-demethoxydaunomycin J. Org. Chem. 1994, 59, 1184-1190
46. Sandanayaka, V.; Mamat, B.; Mishra, R. K.; Winger, J.; Krohn, M.; Zhou, L.; Keyvan, M.; Enache, L.; Sullins, D.; Onua, E.; Zhang, J.; Halldorsdottir, G.; Sigthorsdottir, H.; Thorlaksdottir, A.; Sigthorsson, G.; Thorsteinnsdottir, M.; Davies, D. R.; Stewart, L. J.; Zembower, D. E.; Andresson, T.; Kiselyov, A. S.; Singh, J.; Gurney, M. E. Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy) phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis J. Med. Chem. 2010, 53, 573-585
47. Guthikonda, R. N.; Cama, L. D.; Quesada, M.; Woods, M. F.; Salzmann, T. N.; Christensen, B. G. Structure-activity relationships in the 2-arylcarbapenem series: Synthesis of 1-methyl-2-arylcarbapenems J. Med. Chem. 1987, 30, 871-880
48. Horton, D.; Priebe, W. Synthetic routes to higher-carbon sugars. Reaction of lactones with 2-lithio-1,3-dithiane Carbohydr. Res. 1981, 94, 27-41
49. Czernecki, S.; Ville, G. C-glycosides. 7. Stereospecific C-glycosylation of aromatic and heterocyclic rings J. Org. Chem. 1989, 54, 610-612
50. Kraus, G. A.; Molina, M. T. A direct synthesis of C-glycosyl compounds J. Org. Chem. 1988, 53, 752-753
51. Yang, G.; Franck, R. W.; Byun, H.-S.; Bittman, R.; Samadder, P.; Arthur, G. Convergent C-glycolipid synthesis via the Ramberg-Bäcklund reaction: Active antiproliferative glycolipids Org. Lett. 1999, 1, 2149-2151
52. Oikawa, H.; Suzuki, Y.; Katayama, K.; Naya, A.; Sakano, C.; Ichihara, A. Involvement of Diels-Alder reactions in the biosynthesis of secondary natural products: The late stage of the biosynthesis of the phytotoxins solanapyrones J. Chem. Soc., Perkin Trans. 1 1999, 1225-1232
53. Peng, X.; Lu, H.; Han, T.; Chen, C. Synthesis of a novel triptycene-based molecular tweezer and its complexation with paraquat derivatives Org. Lett. 2007, 9, 895-898